- Conditions
- Alzheimer Disease
- Interventions
- lecozotan SR (SRA-333)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2329–2352
of 22,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV/AIDS
- Interventions
- PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400
- Biological
- Lead sponsor
- International AIDS Vaccine Initiative
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Boston, Massachusetts • Houston, Texas
- Conditions
- Relapsed/Refractory Acute Leukemia
- Interventions
- Revumenib
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 6 Months and older
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
- Conditions
- Symptomatic Severe Aortic Stenosis
- Interventions
- TAVR Implantation with SAPIEN XT, SAVR Implantation
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,032 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 55
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 46 more
- Conditions
- Myelofibrosis
- Interventions
- Azacitidine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Schizophrenia
- Interventions
- TAK-063 20 mg, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta, Epoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Rainbow City, Alabama • Hot Springs, Arizona + 41 more
- Conditions
- Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
- Interventions
- 5 mg Serlopitant Tablets
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Interventions
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy, Non-myeloablative Conditioning regimen, Allogeneic transplant, Autologous transplant, Rituximab maintenance therapy, GVHD Prophylaxis
- Drug · Radiation · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 30
- States / cities
- Duarte, California • La Jolla, California • Stanford, California + 23 more
- Conditions
- Hepatitis C
- Interventions
- Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 35
- States / cities
- Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more
- Conditions
- HIV Infections
- Interventions
- enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 41
- States / cities
- Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
- Conditions
- Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
- Interventions
- Homoharringtonine, Imatinib Mesylate
- Drug
- Lead sponsor
- ChemGenex Pharmaceuticals
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Motor Recovery
- Interventions
- tACS Sham, tACS 10Hz, tACS 20Hz
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Seborrheic Dermatitis
- Interventions
- Roflumilast Foam 0.3%, Vehicle foam
- Drug
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 22
- States / cities
- Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
- Conditions
- Relapsed/Refractory B-cell Malignancies
- Interventions
- UBX-303061
- Drug
- Lead sponsor
- Ubix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Canton, Oklahoma • Houston, Texas
- Conditions
- Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IVA Vulvar Cancer AJCC v7, Vulvar Squamous Cell Carcinoma
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 193
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 130 more
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
- Conditions
- Hypoxemia, Acute Respiratory Failure
- Interventions
- SuperNO2VA nasal positive airway pressure devic, Supplemental oxygen
- Device
- Lead sponsor
- Vyaire Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myeloma
- Interventions
- Topotecan, Cyclophosphamide, Melphalan, Peripheral Blood Stem Cells
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain Tumor
- Interventions
- Proton Beam
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- NTS071
- Drug
- Lead sponsor
- Nutshell Therapeutics (Shanghai) Co., LTD.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Houston, Texas • Fairfax, Virginia
- Conditions
- Other Infectious Diseases
- Interventions
- Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Ischemic Stroke
- Interventions
- Elezanumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Long Beach, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 19 Months
- Enrollment
- 950 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more